Brief: Heidelberg Pharma Secures Financing Commitment From Main Shareholder dievini

Heidelberg Pharma AG

17/02/2022 11:38

Feb 17 (Reuters) - HEIDELBERG PHARMA AG  HPHA.DE :
    * SECURES FINANCING COMMITMENT FROM ITS MAIN SHAREHOLDER
DIEVINI
    * HAS SECURED A FINANCING COMMITMENT IN AMOUNT OF UP TO EUR
36
MILLION FROM ITS MAIN SHAREHOLDER DIEVINI HOPP BIOTECH HOLDING
GMBH & CO. KG, WALLDORF, GERMANY, (DIEVINI)
    * THIS COMMITMENT REPLACES NOT YET FULLY USED FINANCING
COMMITMENT
FROM MARCH 2021
    * DETAILED FORM OF FINANCING WILL BE DECIDED BY MANAGEMENT
AND
SUPERVISORY BOARDS OF HEIDELBERG PHARMA AS WELL AS DIEVINI AT A
LATER DATE
    * FINANCING COMMITMENT WILL ENABLE HEIDELBERG PHARMA TO
ADVANCE
ITS BUSINESS ACTIVITIES, IN PARTICULAR TO COMPLETELY CONDUCT
CLINICAL PHASE I/IIA WITH HDP-101 AND TO FURTHER DEVELOP
CANDIDATES HDP-102 UND HDP-103, IF AND TO EXTENT THAT THIS IS
NOT ACHIEVED THROUGH POTENTIAL ALTERNATIVE CAPITAL MEASURES
    * BASED ON CURRENT PLANNING, COMPANY'S CASH REACH IS SECURED
UNTIL
MID-2023

Source text for Eikon:  ID:nEQ2YX51Ta 
Further company coverage:  HPHA.DE 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))